[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556849":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":28,"centralContacts":44,"locations":50,"responsibleParty":65,"collaborators":28,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":28,"studyType":84,"phases":85,"briefSummary":88,"conditions":89,"keywords":95,"overallStatus":53,"whyStopped":28,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"National University Hospital, Singapore","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Exercise","EXPERIMENTAL","Curated exercises designed to address specific muscle groups and joints that are painful and problematic.\n\nExercises would focus on upper and lower body strength generally. It is anticipated that participants ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training.",[13],"Behavioral: Exercise training",{"label":15,"type":10,"description":16,"interventionNames":17},"Menopausal hormone therapy","Menopausal hormone therapy comprising: 17beta-estradiol topical gel (1.25-2.5 gms) applied daily, and micronized Progesterone 200mg daily for 12 days each month.",[18],"Drug: Menopausal hormone therapy",{"label":20,"type":10,"description":21,"interventionNames":22},"Combination of exercise and menopausal hormone therapy","1. Curated exercises designed to address specific muscle groups and joints that are painful and problematic.\n\n   Exercises would focus on upper and lower body strength generally. It is anticipated that the participants ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training.\n2. Menopausal hormone therapy comprising: 17beta-estradiol topical gel (1.25-2.5 gms) applied daily, and micronized Progesterone 200mg daily for 12 days each month.",[23],"Combination Product: Menopausal hormone therapy + exercise training",{"label":25,"type":26,"description":27,"interventionNames":28},"Standard care","NO_INTERVENTION","Standard care will be provided.",null,[30,34,39],{"type":31,"name":15,"description":32,"armGroupLabels":33,"otherNames":28},"DRUG","Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily Ingest Micronized Progesterone 200mg daily for 12 days each month",[15],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":28},"BEHAVIORAL","Exercise training","Exercises would focus on upper and lower body strength generally. It is anticipated that the participants ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week.",[9],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":28},"COMBINATION_PRODUCT","Menopausal hormone therapy + exercise training","1. Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily and Ingest Micronized Progesterone 200mg daily for 12 days each month\n2. Exercises would focus on upper and lower body strength generally. It is anticipated that patients ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week.",[20],[45],{"name":46,"role":47,"phone":48,"phoneExt":28,"email":49},"Eu-Leong Yong, PhD","CONTACT","67724278","obgyel@nus.edu.sg",[51],{"facility":52,"status":53,"city":54,"state":28,"zip":28,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"National University Hospital","RECRUITING","Singapore","SG",{"type":57,"coordinates":58},"Point",[59,60],103.85007,1.28967,{"lat":60,"lon":59},[63],{"name":64,"role":47,"phone":28,"phoneExt":28,"email":28},"Eu-Leong Yong",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"PRINCIPAL_INVESTIGATOR","Obstetrics & Gynaecology","Professor","100556849","phase-2-the-muse-study-for-menopausal-arthralgia-100556849",false,"NCT06530459","The MUSE Study for Menopausal Arthralgia","The MUScle Strengthening Exercises and Estrogen (MUSE) Randomized Controlled Trial for Menopausal Arthralgia","MUSE","INCLUSION CRITERIA:\n\n1. Patients with muscle stiffness and joint discomfort in various sites, including hands, knees, back, hips, and\u002For shoulders. Patients with pain in only one isolated joint would not be accepted.\n2. Arthralgia symptoms with onset, or has become worse, over the perimenopausal or early postmenopausal period (within 5 years of the menopause).\n3. Women should be at the menopause transition, less than or equal to 59 years old at the time of enrollment, or within 5 years of menopause whichever is earlier.\n\n   .\n4. Arthralgia for at least 3 months (pain lasting beyond normal injury healing period)\n5. Community-dwelling and able to ambulate independently.\n\nEXCLUSION CRITERIA:\n\n1. History of thrombo-embolic diseases, strokes, ischemic heart disease, dementia or psychiatric disorders, active liver disease or renal impairment, severe hyperlipidemia, gout, thyroid disease, systemic lupus erythematosus, rheumatoid arthritis, or other chronic inflammatory conditions.\n2. Pregnancy\n3. Non-adherence to national guidelines for breast cancer screening\n4. High risk for breast cancer\n5. Any joint surgery within the last 6 months\n6. Severe obesity: BMI\\>35\n7. Migraine with aura\n8. Poorly controlled diabetes\n9. Use of any form of female hormone supplementation within the past 12 weeks.\n10. High venous thromboembolism risk\n11. Current cholecystitis, fibroids, or undiagnosed abnormal uterine bleeding.\n12. Current smoker.\n13. History of endometrial, ovarian, peritoneal, cervical, breast or endocrine-dependent cancers.\n14. Receiving treatment for any form of cancer.\n15. History of fragility bone fractures within the 2 years.\n16. Any other cognitive, musculoskeletal, neurological, and cardiorespiratory condition affecting one's ability to participate in the study.",true,"FEMALE","30 Years","59 Years",{"count":82,"type":83},100,"ESTIMATED","INTERVENTIONAL",[86,87],"PHASE2","PHASE3","The investigators plan to conduct a pilot 4-arm, randomized study comprising the following interventions: muscle strengthening exercises (MSE) alone, estrogen therapy (ET) alone, and a combination of MSE and ET, compared to usual care in women with menopausal arthralgia. The aim of this pilot study is to assess the feasibility, patient acceptability, and patient perspectives and logistics of delivering interventions, and practicability of outcome assessment tools in this 4-arm study over a 12-week period.",[90,91,92,93,94],"Arthralgia","Menopause","Perimenopausal Disorder","Joint Pain","Postmenopausal Disorder",[15,96,9,97,98],"Muscle strength","Randomized controlled trial","Midlife women","2024-07-26",{"date":101,"type":102},"2024-07-31","ACTUAL",{"date":104,"type":83},"2024-08-01",{"date":106,"type":83},"2028-04",{"name":5,"class":6},1]